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Abstract 
Purpose: To evaluate the protective and restoring effects of allicin in 7,12-dimethylbenz(a)anthracene 
(DMBA)-induced buccal pouch carcinogenesis.  
Methods: 1 week after receiving allicin (20 mg/kg body weight) orally, the buccal pouches of hamsters 
were painted daily with 0.5% 7,12-dimethylbenz(a)anthracene (DMBA) in liquid paraffin for 14 weeks 
and then every other day for another 2 weeks, after receiving allicin orally and thereafter for 14 weeks. 
The protective effects of allicin was evaluated by measuring the tumour incidence, tumour volume and 
tumour burdens as well as the levels of glycoconjugates were analyzed by using specific colorimetric 
methods. Animals not exposed to allicin and/or DMBA, those exposed to DMBA alone and others 
exposed to allicin alone served as controls.  
Results:  Allicin significantly reduced the tumour incidence, tumour volume and tumour burden. DMBA-
altered glycoconjugates in plasma, buccal mucosa tumour tissues and erythrocyte membrane of tumour 
bearing hamsters were normalized after treated with allicin.  
Conclusion: The results suggest that allicin has considerable potential to protect and restore the cell 
surface glycoconjugates moieties in the presence of allicin or possibly other oral carcinogenic agents. 
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Cancer is characterized by key hallmark 
properties such as cell proliferation, apoptosis 
evasion, invasion, metastasis, and angiogenesis 
[1]. One of the most common malignant diseases 
worldwide is cancer of the oral cavity. In the 
Kingdom of Saudi Arabia (KSA), epidemiological 
studies have shown that tobacco use or shamma 
is the major aetiological factor of oral 
carcinogenesis in KSA [2].  
 
In experimental animals, oral squamous cell 
carcinoma can be induced by continued 
application of potent chemical carcinogens such 
as 7,12-dimethylbenz(a)anthracene (DMBA) and 
nitroquinoline-1-oxide. Since the last six 
decades, the Syrian golden hamsters have been 
used in experimental studies for the evaluation of 
oral carcinogenesis. In it known that the DMBA-
induced hamster buccal pouch carcinogenesis 
model has also histological, biochemical and 
molecular similarities to that of the human oral 
cancer [3]. 
 
Glycoproteins are proteins that have 
carbohydrate moiety attached covalently to their 
peptide backbones. The oligosaccharide moiety 
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of glycoconjugates is involved in the transport of 
metabolites across cell membranes. 
Glycoconjugates are released into the circulation 
through increased turnover, secretion, and/or 
shedding from malignant cells [4]. The increased 
levels are positively correlated with increasing 
stages in oral cavity cancer patients [5].  
 
Elevated levels of glycoconjugates resulting from 
biochemical changes in cell surface 
glycoproteins and glycolipids often occur during 
malignant transformation [6]. In patients with 
malignant neoplasm, altered serum 
glycoconjugates are usually indicators for 
diagnosis, staging, prognostication, treatment 
monitoring, and detecting of early recurrence of 
cancer [7,8]. Lipid bound sialic acid is used as a 
marker for several cancers as well as for the 
prognosis of cancer treatment [9].  
 
Several medical plants and their constituents 
have been reported to prevent experimentally 
induced squamous cell carcinomas [10-12]. Our 
previous studies indicated that medicinal plant 
modulates the effect of circulatory antioxidants 
against oral carcinogenesis [13]. Recently, it was 
reported that cardamom has chemopreventive 
effects against fore stomach papillomagenesis 
[14]. Various phytoconstituents such as 
carotenoids, vitamin C and phenolic acids 
present in medicinal plant possess protective 
effects [15]. In particular, flavonoids (a group of 
plant polyphenolic compounds) are known to 
possess potent antioxidant effects [16]. 
 
Allicin (Figure 1), diallyl thiosulfinate (or S-(2-
propenyl) 2-propene-1-sulfinothioate), is the main 
biologically active compound derived from garlic 
(Allium sativum L.).  It became an object of 
interest due to its potential to confer a vast 
spectrum of health benefits including: 
antimicrobial, antifungal and antiparasitic [17], 
antihypertensive [18], cardioprotective [19], anti-
inflammatory [20] and anticancer activities 
[17,21].  
 
The present study was designed to focus the 
protective role of allicin on cell surface 
glycoconjugate moieties by measuring the 
glycoconjugates of DMBA-induced oral 




Figure 1: Chemical structure of allicin [ S -(2-propenyl) 





7,12-dimethylben[a]anthracene was obtained 
from Sigma Aldrich Chemical Limited (St. Louis, 
MO, USA) while allicin was purchased from 
Shanghai Harvest Pharmaceutical Co., Ltd. 
(Shanghai, China). All other chemicals utilized in 




Male golden Syrian hamsters (Mesocricetus 
auratus) 8-10 weeks old, weighing 80-120 g were 
used for the experiments. The animals were 
obtained from Central Animal House, King Saud 
University, Riyadh, KSA and were housed in 
polypropylene cages at room temperatures (22 ± 
2 ºC) and relative humidity 55 ± 5 % with a 12 hr 
light/dark cycle in an experimental room.  
 
They were provided with Purina chow diet pellets 
(Manufactured by Grain Silos and Flour Mills 
Organization, Riyadh, KSA) and tap water ad 
libitum. Animals were acclimatized for a week 
before the study. All the experimental protocols 
were approved by the Institutional Animal Care 





The Golden Syrian hamsters were randomized 
into four groups of 10 animals each as illustrated 
in the experimental protocol in Figure 2. The left 
buccal pouches of animals allocated in group I 
were painted with liquid paraffin thrice a week for 
14 weeks and used as negative control animals. 
Similarly the left buccal pouches of animals in 
groups II and III were painted with 0.5 % DMBA 
in liquid paraffin thrice a week for 14 weeks [22].  
 
While the animals in group II received no other 
treatment, those in group III receive oral 
administration of allicin (20 mg of powder/ kg 
body weight), starting one week before exposure 
to the carcinogen and continued every other day 
(once in 2 days), until each animal was 
sacrificed. Group IV animals received oral 
administration of allicin (20 mg/kg body weight) 
alone throughout the experimental period. The 
experiment was terminated at the end of 16 
weeks and all animals after giving anesthesia 
were euthanized by cervical dislocation. The 
experiments were designed according to our 
previous studies [10-12]. 
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Figure 2: Experimental protocol for chemoprevention study of allicin against DMBA-induced 
carcinogenesis 
 
The buccal mucosal tissues were immediately 
blotted and kept in an ice bath. Histopathological 
examination was carried out on the buccal 
mucosal tissues for all animals. Briefly, the 
mucosa tissue was fixed in 10 % formalin and 
routinely processed and embedded with paraffin. 
Then, 2-3 µm section were cut in a rotary 
microtome and stained with haematoxylin and 
eosin for examination. Tissue samples were 
weighed and homogenized using appropriate 
buffer in an all glass homogenized with Teflon 
pestle using a specific medium.  
 
The protein-bound hexose in plasma, erythrocyte 
membrane preparation and defatted issues were 
estimated as previously described [23-26] Sialic 
acid estimation was done by the method of 
Warren [27]. Plasma lipid bound sialic acid level 
was determined by the method of Katopodis and 
Stock [28] while fucose was estimated by the 




The values are expressed as Mean±SD and the 
statistical comparisons were performed by one-
way analysis of variance (ANOVA) followed by 
Duncan's multiple range test (DMRT). At 95 % 
confidence interval,p-values less than 0.05 were 




Table 1 shows the tumour incidence, tumour 
volume and tumour burden of the control and 
experimental Syrian hamsters. In DMBA-painted 
hamster (group II), 100 % tumour formation with 
mean tumour volume (358.26 mm3) and tumour 
burden (1110.61 mm3) was observed. Oral 
administration of allicin (20 mg/kg body weight) 
significantly reduced the tumour incidence from 
100 % to 89 %, tumour volume (75.73 mm3) and 
tumour burden (151.46 mm3) in DMBA-painted 
hamsters (group III). No tumour was observed in 
negative control (group I) as well as allicin alone 
treated animals (group IV). 
 
Table 1: Effects of allicin on tumour incidence and volume and burden of control and experimental Syrian 
hamsters in each group 
 
Group 






Group I  
(Negative Control) 0 0 0
a 0b 
Group II (DMBA) 100 % 31 (10) 358.26±32.72a 1110.61±75.42b 
Group III (DMBA + 
allicin) 11 % 2 (1) 75.73±6.13
a 151.46±8.38b 
Group IV  
(allicin alone) 0 0 0
a 0b 
Tumour volume was measured using the formula  where D1, D2 and D3 are the three 
diameters (mm) of the tumour. Tumour burden was calculated by multiplying tumour volume and the number of 
tumours/animal. # Values are expressed as mean ± SD for 10 animals in each group. ap < 0.05, bp < 0.05 
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The histopathological features of control and 
experimental Syrian hamsters in each group are 
provided in Table 2. Different histopathological 
changes (severe keratosis, hyperplasia, 
dysplasia and squamous cell carcinoma of the 
epithelium) were observed in hamsters painted 
with DMBA alone (group II). A mild to moderate 
preneoplastic lesions (hyperplasia (+), keratosis 
(++) and dysplasia (+))were noticed in group III 
animals. 
 
Figure 3 shows the levels of protein bound 
hexose, hexosamine, total sialic acid, lipid bound 
sialic acid and fucose in plasma of control and 
experimental Syrian hamsters in each group. The 
levels of glycoconjugates were significantly 
increased in tumour bearing hamsters (group II) 
as compared to control animals (group I). Oral 
administrations of allicin (20 mg/kg body weight) 
to DMBA painted animals (group III) reverted the 
status of glycoconjugates to near normal 
concentration while the animals treated with 
allicin alone showed no significant difference in 
glycoconjugates levels as compared to control 
animals. A significant decrease (p < 0.05) in the 
levels of erythrocyte membranes protein bound 
hexose, hexosamine and total sialic acid were 
observed in group II hamsters and the increase 
in group III animals when compared to group I. 
The levels of hexose, hexosamine and sialic acid 
were no significant (p < 0.05) deference in group 
IV animals when compared to group I animals 
(Figure 4). 
 
The levels of protein bound hexose, total sialic 
acid and fucose in buccal mucosa tissues of 
control and experimental Syrian hamster in each 
group are shown in Figure 5. The hexose, total 
sialic acid and fucose significantly increased in 
group II animals tissues compared to control rats 
(group I). Oral administration of allicin (20 mg/kg 
body weight) normalized the status of 
glycoconjugates levels in DMBA treated rats 
(group III). No significant differences were 
noticed in the levels of glycoconjugates in Syrian 
hamsters treated with allicin alone when 




In this study allicin significantly reduced the 
DMBA-induced tumour incidence, tumour volume 
and tumour burden. It also normalized the altered 
glycoconjugates in plasma, buccal mucosa 
tumour tissues and erythrocyte membrane of 
tumour bearing hamsters.  
 
Malignant transformation of oral epithelium is 
associated with atypical glycosylation of cell 
surface carbohydrates [30]. In the presence of 
DMBA, the altered levels of protein bound 
carbohydrates during carcinogenesis [31] with 
increased levels of protein bound hexose, 
hexosamine and sialic acid in the plasma [32] 
observed in group II animals is well documented. 
Malignant transformation of oral epithelium is 
often connected with atypical glycosylation of cell 
surface carbohydrates [33]. Increased levels of 
glycoprotein linked with higher proliferative 
activity often occur in ovarian cancer [34]. In 
cancer patients, the high levels of 
glycoconjugates in sera is usually as a result of 
the release of glycoconjugates from the cell 
membrane [35]. Evidence from animal 
experiments suggests that the presence of 
malignant tumours invoke increased hepatic 
synthesis of glycoproteins that can then enter 
into the circulation [36]. Increase in glycoprotein 
has also been reported in hepatic neoplasm [37]. 
This may be due to the elevated hepatic 
synthesis, decreased amounts or deficiency of 
the enzymes involved in the synthesis of cell 
surface glycoproteins. 
 
Higher levels of serum sialic acids have been 
documented in patients with various types of 
cancers including oral carcinoma [38]. In DMBA-
painted animals (group II), the elevated total 
sialic acid level can be explained by a 
spontaneous release of aberrant sialic acid 
containing call surface glycoconjugates [39]. 
 
Table 2: Histopathological features of control and experimental Syrian hamsters in each group (n=10) 
 
Group Keratosis Hyperplasia Dysplasia Squamous cell carcinoma 
Group I  
(Negative Control) - - - - 
Group II (DMBA) +++ +++ +++ ++(10) 
Group III (DMBA + 
allicin) ++ + + ++(1) 
Group IV  
(allicin alone) - - - - 
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Figure 3: Status of glycoconjugates in plasma of control and experimental Syrian hamsters in each 
group. The values that do not share a common superscript letter (a, b and c) between groups differ 
significantly at p < 0.05 (analysis of variance followed by DMRT; n=10). 
 
 
Figure 4: Status of glycoconjugates in erythrocyte membranes of control and experimental Syrian 
hamsters in each group. The values that do not share a common superscript letter (a, b and c) 
between groups differ significantly at p < 0.05 (analysis of variance followed by DMRT; n=10). 
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Figure 5: Status of glycoconjugates in buccal mucosa of control and experimental Syrian hamsters in 
each group. The values that do not share a common superscript letter (a, b and c) between groups 
differ significantly at p < 0.05 (analysis of variance followed by DMRT; n=10). 
 
It may also be due to increase in the activity of 
serum or tissues sialidase. In this study, allicin 
not only prevented the cancer formation but also 
inhibited the abnormalities seen in cell surface 
glycoconjugates in the tumour tissues and 
circulation, which indicates their membrane 




The results suggest that allicin has considerable 
potential to protect the cell surface 
glycoconjugate moieties during oral 
carcinogenesis. Protective effect of allicin is 
probably due to its suppressive effect on 
glycoprotein synthesis by modulating the 
activities of the enzymes involved in the 
glycosylation. Further studies are however 
needed to elucidate the exact molecular 
mechanism for the chemopreventive potential of 
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